NASH - January 2021

NASH - January 2021

Hanmi Pharma expanded its LAPSTriple Agonist, HM15211 into Phase 2 for the treatment of NASH and other diseases

18 Jan 2021

Hanmi Pharma – HM15211 (LAPSTriple Agonist, Phase 2)

  • In recent clinical trials, HM15211 demonstrated 50% or greater fatty liver reduction
  • Within 12 weeks, the fatty liver reduction was as high as 80% compared to that of the placebo control group, and the liver enzyme lowering effect was also statistically significant
  • Based on this data, Hanmi Pharma started its global Phase 2 trial, which received FDA’s Fastrack designation 
  • In addition, LAPSGLP/GCG (Efinopegdutide), licensed out to Merck (Sep’20) has entered Phase 2 this year, and its development as a NASH treatment option will also be accelerated

HM15211 showed as high as 80% fatty liver reduction effect within 12 weeks

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Remarks:

  • HM15211 is a first-in-class GLP-1/GIP/Glucagon triple agonist developed based on their innovative LAPSCOVERY technology
  • The major component glucagon in LAPSTriple agonist plays an important role in addressing 3 disease states:
    • Has a direct role in reducing the fat in the liver and prevents liver fibrosis
    • Activates GLP-1 to release insulin and control appetite
    • Activates GIP to release insulin and have an anti-inflammatory effect
  • This potency of HM15211 being able to target multiple indicators gives Hanmi Pharma an advantage over other competitors

– Akshat Gulati, CI Scientists

For full story click here

Home